Business / Finance

RSS

Durata closes initial public offering of 8,625,000 shares of common stock

Durata Therapeutics today announced the closing of its initial public offering of 8,625,000 shares of common stock at a public offering price of $9.00 per share, before underwriting discounts, including 1,125,000 shares of common stock issued upon the exercise in full by the underwriters of their option to purchase additional shares at the public offering price, less the underwriting discount.

24 Jul 2012

Neogen fourth quarter revenues increase 11.4% to $48,545,000

Neogen Corporation announced today that its revenues for the fourth quarter of its FY 2012, which ended May 31, increased 11.4% from the previous year's comparable quarter to $48,545,000. Net income for the fiscal year's final quarter was $0.25 per share, the same as the prior year's fourth quarter of $0.25 per share.

24 Jul 2012

New investment to fund Chiasma's Octreolin Phase 3 pivotal program for acromegaly

Chiasma, Inc., a privately held biopharma company, announced that it closed a $38.5 million equity financing co-led by new investor Abingworth and current investor MPM Capital that also included investments from existing shareholders 7 Med Health Ventures, ARCH Venture Partners, F3 Ventures and Fredric Price, Chiasma's Chairman & CEO.

23 Jul 2012

Alexza obtains $20 million flexible financing facility from Azimuth Opportunity

Alexza Pharmaceuticals, Inc. announced today that it has obtained a committed equity financing facility under which it may sell up to $20 million of its registered common stock to Azimuth Opportunity, L.P., over an approximately 24-month period.

23 Jul 2012

SUMEC to distribute Aurora's breast MRI technology in China

Aurora Imaging Technology, Inc. is pleased to announce an exclusive China distribution agreement with the SUMEC Group Corporation.

23 Jul 2012

PTC Therapeutics completes $30M financing

PTC Therapeutics, Inc. (PTC) today announced the completion of a $30 million financing. The round included a number of long-term investors such as Credit Suisse First Boston Equity Partners, HBM BioVentures, Vulcan Ventures, Celgene, Delphi Ventures, The Column Group, Novo A/S, and other existing investors.

23 Jul 2012

Sandoz acquires Fougera Pharmaceuticals

Sandoz has completed its USD 1.525 billion acquisition of specialty US dermatology company Fougera Pharmaceuticals on a cash and debt free basis.

23 Jul 2012

When checks and balances in the pharmaceutical marketplace fall short

The Washington Post explores how a trio of very expensive anemia drugs became "superstars" in the marketplace. Also, The Wall Street Journal tracks the process by which certain fake cancer drugs found their way into the United States.

21 Jul 2012

Claimsnet second quarter 2012 revenues increase 12% to $657,000

Claimsnet.com inc., a leading provider of Internet-based claims processing solutions for the healthcare industry, today reported its results for the second quarter of 2012, which ended June 30, 2012.

20 Jul 2012

Cepheid second quarter 2012 revenues increase 21% to $81.0 million

Cepheid today reported revenues for the second quarter of 2012 of $81.0 million, representing growth of 21% from $67.0 million for the second quarter of 2011.

20 Jul 2012

Nuvo Research receives first three Pliaglis marketing licenses from E.U. countries

Nuvo Research Inc., a specialty pharmaceutical company dedicated to building a portfolio of products for the topical treatment of pain today announced that Galderma S.A. (Galderma), a global company dedicated to dermatology has received its first three Pliaglis marketing licenses from E.U. countries.

20 Jul 2012

Cubist second quarter total net revenues increase 30% to $230.6M

Cubist Pharmaceuticals, Inc. today announced results for the second quarter ended June 30, 2012.

20 Jul 2012

athenahealth second quarter total revenue increases 33% to $103.5 million

athenahealth, Inc., a leading provider of cloud-based practice management, electronic health record (EHR), and care coordination services to medical groups, today announced financial and operational results for the second quarter of fiscal year 2012.

20 Jul 2012

Dyax second quarter 2012 total revenues increase to $14.0 million

Dyax Corp. today announced financial results for the second quarter ended June 30, 2012.

20 Jul 2012

BrainStorm completes registered public offering of common stock

BrainStorm Cell Therapeutics Inc., an innovative developer of adult stem cell technologies and Central Nervous System (CNS) therapeutics, today announced that it completed a registered public offering of 19,818,972 shares of common stock at a price per share of $0.29 and warrants to purchase 14,864,229 shares of common stock at an exercise price of $0.29 per share, representing gross proceeds of $5,747,502.

20 Jul 2012

WorldOne announces acquisition of Sermo

WorldOne, the global leader in healthcare insights and intelligence, today announced that it has acquired Sermo, the largest online community of U.S. physicians.

20 Jul 2012

Ellman International acquires Sandstone Medical Technologies

Ellman International, Inc., a global leader in advanced radiofrequency (RF) technology for precision surgical and aesthetic procedures today announced that it has acquired the assets of Sandstone Medical Technologies, LLC., a recognized leader in the aesthetic laser and IPL technology field.

19 Jul 2012

NeoGenomics second quarter 2012 revenue increases 49% to $15.6 million

NeoGenomics, Inc., a leading provider of cancer-focused genetic testing services today reported its results for the second quarter 2012.

19 Jul 2012

Oxford University Press announces major new acquisition

Oxford University Press (OUP) has just announced a major new acquisition that will see the publisher take joint ownership of the Journal of Surgical Case Reports (JSCR).

19 Jul 2012

Champions Oncology operating revenues increase to $7.1M for the year ended April 30, 2012

Champions Oncology, Inc., formerly Champions Biotechnology, Inc., engages in the development of advanced technology solutions and services to personalize the development and use of oncology drugs, announced today its financial results for the year ended April 30, 2012.

19 Jul 2012